Constantino Michael T. 4
4 · Humacyte, Inc. · Filed May 20, 2026
Research Summary
AI-generated summary of this filing
Humacyte (HUMA) Director Michael T. Constantino Buys 11,000 Shares
What Happened Michael T. Constantino, a director of Humacyte, Inc. (HUMA), purchased 11,000 shares of Humacyte common stock on May 18, 2026. The total reported cost was $9,840, based on a weighted average price of approximately $0.89 per share. The filing reports these purchases as open‑market acquisitions (transaction code P).
Key Details
- Transaction date: 2026-05-18; Filing date (Form 4): 2026-05-20 (timely; Form 4s are due within two business days).
- Shares acquired: 11,000 at a weighted average price of $0.89; total reported value $9,840.
- Price range (per footnote): individual trades executed between $0.8922 and $0.8958; weighted average reported as $0.89. The insider offered to provide exact per‑trade quantities/prices upon request.
- Shares owned after transaction: not specified in the provided filing excerpt.
- Transaction code: P = Purchase.
Context This was a straightforward open‑market purchase by a company director. Insider purchases are often watched by investors as a stronger signal than routine sales, but the filing does not state any motive. No derivative exercises, gifts, or tax‑withholding events were reported in this transaction.
Insider Transaction Report
Form 4
Humacyte, Inc.HUMA
Constantino Michael T.
Director
Transactions
- Purchase
Common Stock
[F1]2026-05-18$0.89/sh+11,000$9,840→ 43,950 total
Footnotes (1)
- [F1]The price is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $0.8922 to $0.8958. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Signature
/s/ Michael T. Constantino by Dale A. Sander as Attorney-in-Fact|2026-05-20